“…Currently, there are scales or strategies that evaluate some risks in specific population groups, related to increased mortality, greater functional and cognitive deterioration, greater hospital admissions, greater use of medical consultation and emergency services such as, Vulnerable Population Group (5 -8), Pluripathological Patients (9)(10)(11)(12), Barthel Scale (13), Physiological Conditions that affect the pharmacokinetics of the medications received (14)(15)(16)(17)(18)(19), hyperfrequent users or Polyconsultants (20,21), Polypharmacy (22,23), Narrow-range Drugs (24), Lists of High-Risk Drugs (25-27), Haynes-Sackett Test, Morisky-Green Test, Anticholinergic Risk Scale (28)(29)(30)(31)(32), Drug Interactions of Clinical Relevance (33), the STOPP START criteria (34)(35)(36)(37)(38)(39), Beers Criteria (40,41), DRUID Criteria (42)(43)(44), The Medication Regimen Complexity Index (45), among others; but they do not consider some important variables that are found during pharmaceutical care, which is why the Individual Pharmacological Risk Evaluation Scale (IPRES) of the DETI Method of Pharmaceutical Care and Pharmacotherapeutic Follow-up, by integrating the Sociodemographic, Clinical and Utilization Variables of Health Services and related to medication, allows an individual and comprehensive evaluation of the pharmacological risk to which a patient is exposed.…”